Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia
- 1 March 2004
- journal article
- Published by American Society of Hematology in Blood
- Vol. 103 (5) , 1969-1971
- https://doi.org/10.1182/blood-2003-11-3951
Abstract
Alemtuzumab is a humanized monoclonal antibody directed against the CD52 antigen expressed on all lymphocytes: T cells more than B cells and monocytes.5,6 Alemtuzumab is approved for use in chronic lymphocytic leukemia and is being evaluated in the treatment of other hematologic malignancies as well as autoimmune diseases. The potential efficacy of alemtuzumab in treatment of T-LGL has not been described previously. Herein, we describe a patient with CD52+ T-LGL who, after failing multiple treatment modalities, achieved long-term disease control with alemtuzumab.Keywords
This publication has 6 references indexed in Scilit:
- Clinical features of large granular lymphocyte leukemiaSeminars in Hematology, 2003
- Campath-1H monoclonal antibody therapyCurrent Opinion in Oncology, 2000
- Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to Campath-1HPublished by Elsevier ,1998
- Large Granular Lymphocytic Leukemia: An OverviewHospital Practice, 1998
- Treatment of large granular lymphocyte leukemia with oral low-dose methotrexateBlood, 1994
- A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]Blood, 1994